BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 23143666)

  • 1. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
    Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
    Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
    Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
    Fenske W; Völker HU; Adam P; Hahner S; Johanssen S; Wortmann S; Schmidt M; Morcos M; Müller-Hermelink HK; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):919-28. PubMed ID: 19465749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
    Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
    Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease.
    de Cremoux P; Rosenberg D; Goussard J; Brémont-Weil C; Tissier F; Tran-Perennou C; Groussin L; Bertagna X; Bertherat J; Raffin-Sanson ML
    Endocr Relat Cancer; 2008 Jun; 15(2):465-74. PubMed ID: 18508999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors.
    Barzon L; Pacenti M; Masi G; Stefani AL; Fincati K; Palù G
    Oncology; 2005; 68(4-6):414-21. PubMed ID: 16020971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
    Stenman A; Murtha T; Korah R; Carling T
    Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors].
    Wang CP; Zhang J; Gao J; Liu PP; Wu SF; Zeng X; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):686-90. PubMed ID: 23302311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of lachrymal gland.
    Liao Y; Zeng H; Wang X; Huang Y; Chen N; Ge B; Tang L; Luo Q
    Exp Eye Res; 2009 Jan; 88(1):4-11. PubMed ID: 18955046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
    Ronchi CL; Sbiera S; Volante M; Steinhauer S; Scott-Wild V; Altieri B; Kroiss M; Bala M; Papotti M; Deutschbein T; Terzolo M; Fassnacht M; Allolio B
    PLoS One; 2014; 9(8):e105855. PubMed ID: 25144458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers and targeted therapies for adrenocortical carcinoma.
    Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.